Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB028 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| BIIB028 | DRUG | IV infusion administered twice weekly until disease progression or unacceptable toxicity |
Inclusion Criteria: * Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations. * Age greater than or equal to 18 years at the ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BIIB028 is an investigational small molecule being developed for the treatment of advanced solid tumors. It was studied in a Phase 1 clinical trial in patients with advanced solid tumors. The drug is not approved and remains in clinical development.
BIIB028 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The company conducted a Phase 1 clinical trial of BIIB028 in patients with advanced solid tumors.
BIIB028 is in Phase 1 clinical development. A Phase 1 trial of BIIB028 in patients with advanced solid tumors has been completed. The drug is investigational and has not been approved by regulatory authorities.
BIIB028 has been studied in one clinical trial, NCT00725933, titled 'Administration of BIIB028 to Subjects With Solid Tumors.' This Phase 1 trial enrolled 43 patients with advanced solid tumors in the United States and has been completed.
BIIB028 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial in patients with advanced solid tumors. The drug is still in clinical development and has not been approved for any use.